Providence Capital Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-3
| Closed | – | – | 330 |
|
|
2022
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 362 |
|
|
2022
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 482 |
|
|
2021
Q4 | $0 | Hold |
3
| – | – | ﹤0.01% | 348 |
|
|
2021
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 319 |
|
|
2021
Q2 | $0 | Sell |
3
-4
| -57% | – | ﹤0.01% | 322 |
|
|
2021
Q1 | $0 | Sell |
7
-36,323
| -100% | – | ﹤0.01% | 301 |
|
|
2020
Q4 | $1.67M | Buy |
36,330
+4,563
| +14% | +$210K | 0.68% | 50 |
|
|
2020
Q3 | $1.5M | Buy |
31,767
+1,081
| +4% | +$50.9K | 0.79% | 48 |
|
|
2020
Q2 | $1.57M | Sell |
30,686
-320
| -1% | -$16.3K | 0.89% | 47 |
|
|
2020
Q1 | $1.47M | Buy |
31,006
+1,264
| +4% | +$59.9K | 0.88% | 52 |
|
|
2019
Q4 | $1.75M | Buy |
29,742
+484
| +2% | +$28.4K | 0.94% | 47 |
|
|
2019
Q3 | $1.56M | Buy |
29,258
+287
| +1% | +$15.3K | 0.92% | 53 |
|
|
2019
Q2 | $1.45M | Buy |
28,971
+9,993
| +53% | +$500K | 0.86% | 54 |
|
|
2019
Q1 | $991K | Buy |
18,978
+547
| +3% | +$28.6K | 0.62% | 70 |
|
|
2018
Q4 | $880K | Buy |
18,431
+630
| +4% | +$30.1K | 0.6% | 71 |
|
|
2018
Q3 | $894K | Buy |
17,801
+247
| +1% | +$12.4K | 0.58% | 72 |
|
|
2018
Q2 | $885K | Buy |
17,554
+361
| +2% | +$18.2K | 0.62% | 72 |
|
|
2018
Q1 | $840K | Buy |
17,193
+1,274
| +8% | +$62.2K | 0.63% | 72 |
|
|
2017
Q4 | $706K | Buy |
+15,919
| New | +$706K | 0.55% | 68 |
|